GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Scaled Net Operating Assets

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Scaled Net Operating Assets : -0.05 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sichuan Kelun-Biotech Biopharmaceutical Co's operating assets for the quarter that ended in Dec. 2023 was HK$1,073.4 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's operating liabilities for the quarter that ended in Dec. 2023 was HK$1,225.4 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Total Assets for the quarter that ended in Jun. 2023 was HK$2,801.9 Mil. Therefore, Sichuan Kelun-Biotech Biopharmaceutical Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was -0.05.

Sichuan Kelun-Biotech Biopharmaceutical Co Scaled Net Operating Assets Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Scaled Net Operating Assets Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Scaled Net Operating Assets
-0.46 -0.37 -0.14

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial - - -0.28 -2.02 -0.05

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets falls into.


Sichuan Kelun-Biotech Biopharmaceutical Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(1073.449-1225.403)/1109.06
=-0.14

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3838.896 - 2765.447
=1073.449

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1290.941 - 6.03 - 59.508
=1225.403

Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Jun. 2023 )
=(1073.449-1225.403)/2801.856
=-0.05

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3838.896 - 2765.447
=1073.449

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1290.941 - 6.03 - 59.508
=1225.403

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Scaled Net Operating Assets
Comparable Companies
HKSE:01530 HKSE:02162 HKSE:06826 HKSE:09969 HKSE:01541 HKSE:09966 HKSE:06660 HKSE:01952 HKSE:02105 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Website
http://www.kelun-biotech.com
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines